KR20160033779A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20160033779A
KR20160033779A KR1020167004630A KR20167004630A KR20160033779A KR 20160033779 A KR20160033779 A KR 20160033779A KR 1020167004630 A KR1020167004630 A KR 1020167004630A KR 20167004630 A KR20167004630 A KR 20167004630A KR 20160033779 A KR20160033779 A KR 20160033779A
Authority
KR
South Korea
Prior art keywords
cancer
aurka
day
tsa
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167004630A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 에이치. 폴리메로포울로스
루이스 윌리엄 리카멜레
크리스티안 라베단
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20160033779A publication Critical patent/KR20160033779A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167004630A 2013-08-22 2014-08-22 암 치료 Ceased KR20160033779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US61/869,039 2013-08-22
PCT/US2014/052209 WO2015027121A2 (en) 2013-08-22 2014-08-22 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032020A Division KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Publications (1)

Publication Number Publication Date
KR20160033779A true KR20160033779A (ko) 2016-03-28

Family

ID=51794948

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020167004630A Ceased KR20160033779A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020237010047A Abandoned KR20230047203A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217002758A Active KR102315528B1 (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020237010047A Abandoned KR20230047203A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217002758A Active KR102315528B1 (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Country Status (12)

Country Link
US (6) US20160199323A1 (cg-RX-API-DMAC7.html)
EP (2) EP3036007B1 (cg-RX-API-DMAC7.html)
JP (4) JP2016528297A (cg-RX-API-DMAC7.html)
KR (5) KR20160033779A (cg-RX-API-DMAC7.html)
CN (2) CN110585184A (cg-RX-API-DMAC7.html)
AU (4) AU2014308700A1 (cg-RX-API-DMAC7.html)
CA (1) CA2921036A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016000397A1 (cg-RX-API-DMAC7.html)
EA (1) EA037667B1 (cg-RX-API-DMAC7.html)
ES (1) ES2755983T3 (cg-RX-API-DMAC7.html)
MX (1) MX381429B (cg-RX-API-DMAC7.html)
WO (1) WO2015027121A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623011B1 (en) * 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
EP1766086A4 (en) 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
GB0519405D0 (en) 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
KR20090014393A (ko) 2006-05-26 2009-02-10 셀진 코포레이션 조합 요법에서 면역조절 화합물을 사용하는 방법 및 조성물
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20110301055A1 (en) 2008-12-05 2011-12-08 Nicholas James Dickens Methods for determining a prognosis in multiple myeloma
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
EP2602330A1 (en) 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EP3623011B1 (en) 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Also Published As

Publication number Publication date
EP3616754A1 (en) 2020-03-04
KR20210013343A (ko) 2021-02-03
CN105579101A (zh) 2016-05-11
EA201690445A1 (ru) 2016-06-30
AU2014308700A1 (en) 2016-02-25
US20230257471A1 (en) 2023-08-17
EP3036007B1 (en) 2019-10-09
AU2022202183B2 (en) 2023-09-28
CL2016000397A1 (es) 2017-03-17
EP3036007A2 (en) 2016-06-29
WO2015027121A2 (en) 2015-02-26
JP2021105005A (ja) 2021-07-26
JP2019167351A (ja) 2019-10-03
KR102315528B1 (ko) 2021-10-21
KR20210127821A (ko) 2021-10-22
US12590162B2 (en) 2026-03-31
US20190211107A1 (en) 2019-07-11
ES2755983T3 (es) 2020-04-24
MX2016002307A (es) 2016-06-15
NZ716668A (en) 2021-02-26
US10265282B2 (en) 2019-04-23
EA037667B1 (ru) 2021-04-28
AU2022202183A1 (en) 2022-04-21
US11667718B2 (en) 2023-06-06
US20180256522A1 (en) 2018-09-13
CN110585184A (zh) 2019-12-20
US20260193368A1 (en) 2026-07-09
US11078289B2 (en) 2021-08-03
AU2021261882B2 (en) 2022-04-14
WO2015027121A3 (en) 2015-05-14
US20210324093A1 (en) 2021-10-21
AU2019261718A1 (en) 2019-11-28
MX381429B (es) 2025-03-12
US20160199323A1 (en) 2016-07-14
AU2021261882A1 (en) 2021-12-02
JP2016528297A (ja) 2016-09-15
CA2921036A1 (en) 2015-02-26
JP2023088996A (ja) 2023-06-27
KR20170126018A (ko) 2017-11-15
KR20230047203A (ko) 2023-04-06

Similar Documents

Publication Publication Date Title
US12590162B2 (en) Cancer treatment
US20190282541A1 (en) Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
ES3018607T3 (es) Tricostatina A para el uso en el tratamiento del mieloma múltiple
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
NZ716668B2 (en) Cancer treatment
HK1226349A1 (en) Cancer treatment
HK1226349B (en) Cancer treatment
JP2025523114A (ja) Atリッチ相互作用ドメイン含有タンパク質1a(arid1a)突然変異癌を処置するためのezh2阻害療法
TW201021801A (en) A pharmaceutical composition for the treatment of cancers
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20160223

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160223

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161220

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170804

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171103